What type of study is this?

This is a Experimental Study study (also classified as: Cohort Study).

A novel ligustrazine-based nanodelivery system protects against doxorubicin-induced cardiotoxicity by targeting the SIRT5–DUSP1 axis for mitochondrial repair

View Full Paper

Ask AI

Bookmark

Authors

This novel nanodelivery system targets the SIRT5–DUSP1 axis to mitigate mitochondrial dysfunction in cardiotoxicity.

LIG–Na significantly ameliorates doxorubicin-induced cardiac dysfunction and mitochondrial dysregulation.
The study utilized SIRT5/DUSP1/PHB2CKO and DUSP1 transgenic mice to demonstrate the therapeutic effects of ligustrazine.
Mitochondrial function was effectively restored following treatment with LIG–Na, indicating its promising cardioprotective potential.
Bioinformatics and advanced techniques were combined to investigate the underlying mechanisms of mitochondrial homeostasis.

Shi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark